Mayor overspending on cannabis experiment

Preparations for an experiment to grow and sell cannabis legally over a three-year trial period has so far cost the City Council 212,321 kroner, Metroxpress newspaper reports. 

Venstre and Konservative council members have accused Mayor Frank Jensen of wasting taxpayer money because the government has already said no to going through with the experiment.

"Frank Jensen might as well throw thousand kroner bills out onto the city hall square," Flemming Steen Munch (V) told Metroxpress.

Copenhagen should lead the way
The mayor responded by saying that the government also ruled against injection rooms before the two facilities opened in Vesterbro.

"Copenhagen should lead the way with specific solutions to difficult problems, so that it's money well spent," Jensen said.

"We now have a specific model that fits Copenhagen." 





  • How internationals can benefit from joining trade unions

    How internationals can benefit from joining trade unions

    Being part of a trade union is a long-established norm for Danes. But many internationals do not join unions – instead enduring workers’ rights violations. Find out how joining a union could benefit you, and how to go about it.

  • Internationals in Denmark rarely join a trade union

    Internationals in Denmark rarely join a trade union

    Internationals are overrepresented in the lowest-paid fields of agriculture, transport, cleaning, hotels and restaurants, and construction – industries that classically lack collective agreements. A new analysis from the Workers’ Union’s Business Council suggests that internationals rarely join trade unions – but if they did, it would generate better industry standards.

  • Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    The numbers are especially striking amongst the 3,477 business and economics students polled, of whom 31 percent elected Novo Nordisk as their favorite, compared with 20 percent last year.